Researchers Tapping the Genome to Extend Life and Reverse Disease

November 19, 2026

By Deborah Borfitz 

November 19, 2026 | As has been extensively demonstrated in mice, it is entirely possible to slow or reverse biological aging. Work currently underway at Harvard University’s Wyss Institute for Biologically Inspired Engineering aims to take interventions that makes aged cells and tissues “function younger” into treatments for humans plagued by an assortment of age-related diseases, according to Alex Plesa, Ph.D., one of its resident scientists.   

Among the latest findings is that an RNA processing factor known as serine/arginine-rich splicing factor 1 (SRSF1) has “very potent, demonstrable” anti-aging and rejuvenation effects, reports George Church, Ph.D., founding core faculty member at the Wyss Institute. It was one of the chief findings of a recently published study that notably included Kaplan-Meier plots measuring the probability of survival (Nature Aging, DOI: 10.1038/s43587-026-01234-8).   

The SRSF1 gene is one of the SR protein family of genes that “individually do something powerful—they shift the Kaplan-Meier survival curve to the right by a significant amount, typically in the 10% to 20% range,” says Church. “Wouldn’t it be cool if some of these were additive or maybe even synergistic?” 

The addition of SRSF1 to the pantheon of genes that increase longevity is remarkable in terms of impact, he notes. It takes a trio of transcription factors—OCT4, SOX2, and KLF4—to get an equivalent reversal of cellular aging. The so-called OSK genes are a subset of the four Nobel Prize-winning Yamanaka factors (OSKM), discovered in 2006, which revolutionized biology by proving that specialized adult cells can be rewound into a stem-cell state.  

The fourth gene, c-Myc, is associated with cancer risk, sparking a quest for safer ways to rejuvenate cells. Work in the epigenetic field paved the way for “transcriptomic clocks” estimating biological age based on RNA and gene expression levels by proving that machine learning could extract accurate biological age signals from high-dimensional molecular data. Among the early innovators in this active research area is Plesa, who together with postdoctoral fellow Sascha Jung, Ph.D., developed the latest transcriptomic age predictor.  

Unlike those in the longevity field, the Food and Drug Administration doesn’t care all that much about Kaplan-Meier plots in mice, and they’re impractical to use for prospective human longevity studies, says Church. But the agency gets “fired up” about reversing diseases of aging, opening regulatory pathways for biotech researchers.  

In the latest study, SRSF1 was found to extend the median lifespan of aged mice by about 14%—equivalent to roughly 10 human years. Since the therapy was delivered using a virus that mainly targets the liver, the systemic effects were likely due to the rejuvenation of this one organ. The target was initially identified in experiments with fibroblasts, the connective tissue cells that get dysregulated with aging and can form scars in multiple organs.  

Researchers therefore have follow-on studies planned to learn if SRSF1 might have therapeutic use for the treatment of liver pathologies as well as different fibrotic indications, including scarring occurring in the liver, lung, and kidneys. RegulaBio, an early-stage biotechnology company that will be spinning out of the Wyss Institute by Plesa and Church, will be pursuing this line of research. 

Their approach will likely mirror that of Rejuvenate Bio, another Harvard spin-out cofounded by Church in 2018 alongside Noah Davidsohn (chief scientific officer) and Daniel Oliver (CEO), where candidate rejuvenation genes are first identified in human cells and mice before advancing to human clinical applications, says Plesa. “[But first], we want to do a few more studies and make sure we have all the data that we need for embarking on the drug development process.” 

Gauging Age  

The Nature Aging paper represents Plesa’s Ph.D. work in the Church lab at Harvard Medical School, where he was challenged to identify new genes that could make old cells young. The first order of business was to develop a way to measure aging in a dish by looking at gene expression in old versus young human cells.  

To understand which genes tracked with aging and predict a cell’s age from gene expression alone, researchers split all the genes being expressed into seven different cellular processes, including those involved in maintaining the epigenome, stress response, and translation, Plesa explains. He likened the approach to gauges in a car, each indicating how well different parts are operating and collectively painting a picture of the overall condition. 

The team first identified about 90 candidate genes based on how central they are to the networks of genes that change with human aging, he continues. Each of these was turned on in fibroblasts from multiple aged human donors, and the new measurement tool was used to see if the cells became younger or older. SRSF1 emerged as the top candidate.  

Different assays for cell health were used to validate SRSF1 before it was administered with a single injection of a liver-targeting adeno-associated virus (AAV) into 18-month-old mice (equivalent to 60 human years), says Plesa. The gene was turned on in the mice using the small molecule doxycycline in their food every other week until they died. Relative to the mice serving as controls, the treated mice not only lived longer but also aged and grew frail more slowly.  

Gene Cocktails 

The more mature Rejuvenate Bio is on a mission to develop targeted gene and epigenetic therapies to reverse aging and treat age-related chronic diseases. About three years ago, the company published the first gene therapy study delivering the Yamanaka factors in aged mice, minus the problematic c-Myc gene, using doxycycline as an on-off switch to prevent cell identity loss and thereby mitigating at least some of their safety risks, says Church.  

Its first human trial of a targeted treatment for arrhythmogenic cardiomyopathy is expected to begin soon, boosting fibroblast growth factor 21 (FGF21) activity in an AVV delivery system. The approach is also being tested in combination with suppression of transforming growth factor beta 1 (TGF-β1) signaling via a soluble transforming growth factor beta receptor 2 (sTGFβR2) for mitral valve disease in animals.  

The central problem with any approach is “you have to get everything right at once,” Church says. That means “it might not be one-size-fits-all for every tissue in the body. You may need more than one gene.” 

Plesa agrees that multiple factors are going to be needed to reverse cellular aging, and while the Yamanaka factors are furthest along, he expects the mix to include more factors like SRSF1, which can rejuvenate cells without changing their identity. In addition to ongoing discovery work by Davidsohn and Church, multiple companies (including San Francisco-based NewLimit) are looking for transcription factors appropriate for treating different tissues. The tools being deployed include large-scale bioinformatics platforms combining single-cell RNA sequencing and spatial transcriptomics to map how individual cells behave and interact inside tissues over time.   

“There are a few genes that we can reliably turn on or off to see a benefit in survival and, ideally, also see a benefit in certain diseases,” says Plesa. The question now being asked is which ones are additive in shaping disease risk and which ones can be applied to treating it—and how to “make the most of the tools we have.”  

Aging Clocks 

Transcriptomic clocks are more difficult to develop than the more ubiquitous epigenetic clocks based on DNA methylation, which enjoy gold standard status and out-of-the-box availability. Epigenetic clocks are also at least 30 times more expensive to deploy at scale compared to the do-it-yourself RNA sequencing method used in the latest research, says Plesa, ballparking the cost per test at $350 and $10, respectively.  

RNA clocks don’t give you just a single number, he adds. They also reveal the specific molecular shifts behind the score to understand what parts of cells are younger or older based on changes in their gene expression.  

DNA methylation sites are not well understood and don’t correlate well with gene expression, notes Plesa. Methylation occurring between genes can be particularly perplexing.   

When Plesa and his team built their own transcriptomic clock a few years ago, few other such clocks had been published and the ones that were didn’t suit their intended research use. Many other options now exist, including multi-species, multi-tissue transcriptomic clocks emerging from the Gladyshev lab at Harvard Medical School and the Brigham and Women’s Hospital Division of Genetics. 

For now, biological aging clocks are primarily being used outside of clinical settings, says Church. “A lot of [the epigenetic clocks] are popular just because people like measuring things, but I don’t know how many of them are actually saving lives.” That could well change, at a minimum through their use in research, leading to therapeutic advances.  

To that end, Plesa says, next steps include running more studies in mice to find good age-associated diseases that could potentially be treated with SRSF1 and initiating safety and toxicology studies. First-in-human testing is at least a few years away.  

Humanity awaits. “Aging is going to kill 90% of us,” Church quips. “This is the ultimate non-specialized disease ... that takes no prisoners.”